Tactile Systems Technology’s (TCMD) “Hold (C)” Rating Reiterated at Weiss Ratings

Weiss Ratings reaffirmed their hold (c) rating on shares of Tactile Systems Technology (NASDAQ:TCMD) in a report published on Wednesday morning,Weiss Ratings reports.

A number of other equities analysts have also weighed in on the company. William Blair raised Tactile Systems Technology to a “strong-buy” rating in a research note on Tuesday, August 5th. Lake Street Capital assumed coverage on shares of Tactile Systems Technology in a report on Friday, October 3rd. They set a “buy” rating and a $23.50 price target for the company. Wall Street Zen upgraded shares of Tactile Systems Technology from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Finally, B. Riley restated a “neutral” rating and set a $13.00 price target (up previously from $12.00) on shares of Tactile Systems Technology in a report on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $16.83.

Tactile Systems Technology Stock Performance

NASDAQ TCMD opened at $14.22 on Wednesday. The stock’s fifty day moving average is $13.38 and its two-hundred day moving average is $11.94. The firm has a market capitalization of $316.96 million, a P/E ratio of 22.94 and a beta of 1.04. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.36 and a current ratio of 3.79. Tactile Systems Technology has a fifty-two week low of $8.61 and a fifty-two week high of $21.10.

Tactile Systems Technology (NASDAQ:TCMD) last released its quarterly earnings data on Monday, August 4th. The company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. The company had revenue of $78.91 million for the quarter, compared to analyst estimates of $73.93 million. Tactile Systems Technology had a return on equity of 7.72% and a net margin of 5.06%. Tactile Systems Technology has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Tactile Systems Technology will post 0.7 earnings per share for the current year.

Insider Buying and Selling

In other Tactile Systems Technology news, CEO Sheri Louise Dodd sold 7,762 shares of Tactile Systems Technology stock in a transaction on Friday, August 8th. The stock was sold at an average price of $12.36, for a total value of $95,938.32. Following the sale, the chief executive officer owned 173,479 shares in the company, valued at $2,144,200.44. The trade was a 4.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Tactile Systems Technology

Institutional investors and hedge funds have recently modified their holdings of the company. GAMMA Investing LLC raised its holdings in shares of Tactile Systems Technology by 64,350.0% in the 1st quarter. GAMMA Investing LLC now owns 2,578 shares of the company’s stock valued at $34,000 after buying an additional 2,574 shares during the period. Oxford Asset Management LLP purchased a new stake in shares of Tactile Systems Technology in the 2nd quarter valued at $124,000. Pinnacle Wealth Management Advisory Group LLC purchased a new stake in shares of Tactile Systems Technology in the 2nd quarter valued at $134,000. EP Wealth Advisors LLC purchased a new stake in shares of Tactile Systems Technology in the 1st quarter valued at $138,000. Finally, Algert Global LLC purchased a new stake in shares of Tactile Systems Technology in the 1st quarter valued at $160,000. Hedge funds and other institutional investors own 83.43% of the company’s stock.

Tactile Systems Technology Company Profile

Tactile Systems Technology, Inc, a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers.